ClinicalTrials.gg
CompletedNCT03266965Updated Oct 8, 2020

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

A Phase 1 interventional study of Carbidopa and L-Histidine in Multiple Sclerosis, sponsored by University of Miami. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-08.

Sponsored by University of Miami · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
710th of 879
18 · median 50
Started
2018
with 61 others
Phase 1
105 of 1,192
18 open now
Registered
604th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 710th largest by enrollment of the 879 interventional ones that give a count, is one of 62 that started in 2018, is one of 105 in phase 1, and was the 604th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The histaminergic system is phylogenetically one of the oldest parts of the nervous system but it is a relatively recent discovery. It is involved with several vegetative functions like sleep, attention and learning, feeding and satiety, working memory, cognition, depression, and most of all arousal and energy

Read the detailed description
  1. Establish in an open label clinical trial the tolerability and safety of various doses of l-histidine and lodosyn that may increase levels of l-histidine and histamine in the serum and cerebrospinal fluid (CSF).
  2. Perform pharmacokinetic studies in serum and CSF of study subjects the levels of l-histidine and histamine after treatment with various combination of l-histidine and lodosyn.
  3. Preliminary information will also be collected on the effects of this intervention on alleviation of fatigue.

The findings from this study go beyond the effects of histamine on fatigue. If central histamine can be increased by the strategy outlined above, a number of other vegetative hypothalamic functions intricately associated with fatigue including sleep, cognition and satiety need to be examined in MS patients in future studies.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Fatigue
  • Histamine
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between the ages of 18 and 60 will be eligible.
  2. Subjects should be in good physical health without history of chronic illness and should be generally considered healthy.
  3. Spouses or caregivers of patients with MS would be encouraged to participate.

Inclusion Criteria for Patients with Multiple Sclerosis (MS):

  1. Patients with MS regardless of the disease type, who experience severe fatigue will be eligible to participate.
  2. Fatigue Severity Score of >/= 4.0 will qualify as long as all other inclusion / exclusion criteria are met.
  3. Established MS by McDonald Criteria - 2010 Revision (24). Relapse Remitting (RR) and progressive forms of MS are eligible
  4. Severe fatigue that has lasted greater than 6 months
  5. Clinically stable on a current therapy with any Disease Modifying Therapy (DMT)

Exclusion criteria

Exclusion Criteria for Healthy Volunteers:

  1. Adults unable to give due to cognitive impairment or mental disorders.
  2. Children below the age of consent
  3. Pregnant women
  4. Prisoners
  5. History of chronic disorders like hypertension, diabetes, hyperlipidemia, depression, hypothyroidism etc. that require chronic treatment
  6. Known chronic fatigue syndrome
  7. Blood disorders or coagulopathy
  8. Chronic allergies or history of asthma.
  9. Using antihistamines, bronchodilators or H2 blockers for hyperacidity
  10. Using medications for sleep, or known sleep disorders
  11. Any medication or condition deemed unsuitable by the PI

Exclusion Criteria for Patients with Multiple Sclerosis (MS):

  1. Adults unable to give informed consent due to cognitive impairment or mental disorders.
  2. Children below the age of consent
  3. Pregnant women
  4. Prisoners
  5. Systemic disorders known to cause fatigue such as severe anemia, infections, chronic systemic infectious or inflammatory disorders, including known disorders.
  6. Chronic fatigue syndrome
  7. Hypothyroidism
  8. Systemic
  9. Undergoing chemotherapy
  10. Depression
  11. Sleep disorders including narcolepsy, excessive day-time sleep.
  12. History of substance abuse
  13. Excessive consumption of coffee or over-the-counter stimulants
  14. Concomitant medications of amantadine, methylphenidate, amphetamines, pemoline, barbiturates, tizanidine, Monoamine oxidase inhibitor (MAO) inhibitors, benzodiazepines, barbiturates, tricyclic antidepressants, antihistamines, H2 blockers for gastro-esophageal reflux disease (GERD), selective serotonin reuptake inhibitors (SSRIs) and any other medication that in the opinion of the PI should be excluded.
  15. Patients who were using modafinil for treatment of fatigues prior to the study may participate but will be required to undergo a of 2 weeks prior to entry into the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Histidine Intervention Group

    A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.

    Drug: Carbidopa · Dietary Supplement: L-Histidine

Interventions

  • All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.

    Also known as: Lodosyn

  • Dietary supplementL-Histidine

    Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.

06

What researchers measure

Primary outcomes

  1. Number of adverse events experienced by participants.

    All adverse and serious adverse events reported during the study will be analyzed and tabulated. No quantitative statistical analysis will be performed. The primary goal of this study is to establish that this intervention is safe and possibly effective.

    Time frame: 30 days

Secondary outcomes

  1. Change extent of fatigue.

    At the conclusion of the study, each individual would have completed a screening and baseline visit without any intervention and two weekly visits during intervention with the study medications. The two evaluations off drug will be compared to the two evaluations on drug. A drop of the Fatigue Severity Scale (FSS) score by 1 point or more will be considered a response. Once the information is converted into a binary function of response / no response, the data is amenable to conditional logistic regression analysis.

    Time frame: Screening(0 day), baseline(15 days) and final visit(30 days)

  2. Change in Quality of life.

    Multiple Sclerosis Quality of Life (MSQOL) scales will be used to measure the change in Quality of Life. Based on the scale, there will be a 0 to 100 with a higher score indicating a higher quality of life.

    Time frame: Screening(0 day), baseline(15 days) and final visit(30 days)

  3. Change of fatigue impact scale.

    Modified Fatigue Impact Scale (MFIS) scale will be used to evaluate the physical, cognitive and psychosocial scores. The score ranges from 0 to 84 with a lower score, lower side effects of fatigue.

    Time frame: Screening(0 day), baseline(15 days) and final visit(30 days)

  4. Change of visual pain.

    Visual analogue scale to evaluate the pain by using a numerical scale for 0 to 10 with a lower score, less visual pain.

    Time frame: Screening(0 day), baseline(15 days) and final visit(30 days)

  5. Change of daytime sleepiness.

    Epworth sleep scale to rate the probability of falling asleep during daytime on a scale of 0 to 24 with a lower score the lower the symptoms of sleepness.

    Time frame: Screening(0 day), baseline(15 days) and final visit(30 days)

  6. Change of hunger sensitivity.

    Hunger Satiety Scale to determine the extent of hunger and fullness by using a 1 to 10 score range with a higher score indicating a higher hunger sensitivity.

    Time frame: Screening(0 day), baseline(15 days) and final visit(30 days)

07

Study locations

1 site
  • University of Miami
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Aug 2020, 28 months.

Of 53 non-industry phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's 28 months is below that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2017
First posted
Aug 30, 2017
StartActual
Mar 23, 2018
Primary completionActual
Aug 7, 2020
CompletionActual
Aug 7, 2020
Last update
Oct 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03266965
Collaborators
United States Department of Defense
Responsible party
Kottil W. Rammohan (Professor Of Clinical Neurology, University of Miami) — Principal investigator
First posted
Aug 30, 2017
Start date
Mar 23, 2018
Primary completion
Aug 7, 2020
Completion
Aug 7, 2020
Last update
Oct 8, 2020

Study contacts

Kottil Rammohan, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carbidopa · Histidine

Start the discussion